1 INTRODUCTION {#SEC1}
==============

Traditional genome-wide association studies (GWAS) test one single nucleotide polymorphism (SNP) at a time for association with disease, overlooking interplay between SNPs within a gene or pathway, missing weak signal that aggregates in sets of related SNPs and incurring a severe penalty for multiple testing. More recently, sets of SNPs have been tested jointly in a gene-set enrichment style approach ([@btt177-B15]) and also in seeking association between rare variants within a gene and disease ([@btt177-B4]; [@btt177-B40]). As next-generation sequencing rapidly becomes the norm, these set-based tests, complementary to single SNP tests, will become increasingly important. However, existing methods for testing sets of SNPs do not handle confounding such as arises when related individuals or those of diverse ethnic backgrounds are included in the study. Such confounders, when not accounted for, result in loss of power and spurious associations ([@btt177-B3]; [@btt177-B31]). Yet, it is precisely these richly structured cohorts that yield the most power for discovery of the genetic underpinnings of complex traits. Moreover, such structure typically presents itself as data cohorts become larger and larger to enable the discovery of weak signals.

In this article, we introduce a new, powerful and computationally efficient likelihood ratio-based set test that accounts for rich confounding structure. We demonstrate control of type I error as well as improved power over the more traditionally used score test. Finally, we demonstrate application of our approach to two real GWAS datasets. Both datasets showed evidence of spurious association owing to confounders in an uncorrected analysis, whereas application of our set test corrected for confounders and uncovered signal not recovered by univariate analysis. Finally, our test is extremely computationally efficient owing to development of a new linear mixed model (LMM) algorithm also presented herein, which makes possible, for example, set analysis of the 15 000 individual Wellcome Trust Case Control Consortium (WTCCC) data.

Several approaches have been used to jointly test sets of SNPs: *post hoc*, gene-set enrichment in which univariate *P*-values are aggregated ([@btt177-B15]), operator-based aggregation such as 'collapsing' of SNP values ([@btt177-B5]; [@btt177-B21]), multivariate regression, typically penalized ([@btt177-B29]; [@btt177-B35]) and variance component (also called kernel) models such as a LMMs ([@btt177-B33]; [@btt177-B39], [@btt177-B40]).

Our approach is based on the LMM, which can equivalently be viewed as a multivariate regression. In particular, use of a LMM with a specific form of genetic similarity matrix is equivalent to regressing those SNPs used to estimate genetic similarity on the phenotype ([@btt177-B14]; [@btt177-B28]). If one uses only SNPs to be tested in the similarity matrix as in Wu *et al.* ([@btt177-B39], [@btt177-B40]), then one is effectively performing a multivariate regression test. However, by also using SNPs that tag confounders in a separate similarity matrix, our model can additionally correct for confounders, as has been done in a single-SNP test GWAS setting ([@btt177-B16]; [@btt177-B24]; [@btt177-B28]; [@btt177-B42]). Finally, our approach allows one to condition on other causal SNPs, by way of the similarity matrix, for increased power, again, as has been done in single-SNP test setting ([@btt177-B2]; [@btt177-B28]; [@btt177-B36]).

The use of LMMs to correct for confounders in GWAS is now widely accepted because this approach has been shown capable of correcting for several forms of genetic relatedness such as population structure and family relatedness ([@btt177-B1]; [@btt177-B16]; [@btt177-B31]; [@btt177-B42]). Independently, the use of LMMs to jointly test rare variants has become prevalent ([@btt177-B39], [@btt177-B40]). In our new approach, we marry the aforementioned uses of LMMs to perform set tests in the presence of confounders within a single, robust and well-defined statistical model.

Because of the aforementioned equivalence, our approach can also be viewed as a form of linear regression with two distinct sets of covariates. The first set of covariates consists of SNPs that correct for confounders (and other causal SNPs), i.e. those that predict race and relatedness, for example. Inclusion of these SNP covariates makes the data for individuals independently and identically distributed (i.e. knowing the value of these SNPs induces a common distribution from which the individuals are drawn). The second set of covariates consists of SNPs for a given set of interest, such as those SNPs belonging to a gene. We call our approach FaST-LMM-Set.

Computing the likelihood for our model---an LMM with two random effects---is, naively, extremely expensive, as it scales cubically with the number of individuals (e.g. [@btt177-B26]). For example, on the 15 000 individual WTCCC dataset we analyse, currently available algorithms would need to compute and store in memory genetic similarity matrices of dimension 15 000 × 15 000 and repeatedly perform cubic operations on them to test just a single set of SNPs---a practically infeasible approach. However, extending our previous work that made LMMs with a single random effect linear in the number of individuals ([@btt177-B24]) to the two-variance component model needed here, we bypass this computational bottleneck, yielding a new two-random-effects algorithm, which is linear in the number of individuals. This advance enables us to analyse datasets, which could not otherwise be practically analysed, such as the 15 000 individual WTCCC cohort ([@btt177-B38]). As a case in point, using the naïve cubic approach to test the gene set IL23R (containing 14 SNPs) took 13 h as compared with 1 min for our new approach (all on a single processor), demonstrating a speedup factor of 780 (and significantly less memory usage because the genetic similarity matrix need never be computed with our approach).

2 METHODS {#SEC2}
=========

Let denote a multivariate Normal distribution in with mean and covariance matrix **.** The log likelihood of a one-variance-component LMM in the linear regression view is given by where is a vector of phenotype values for individuals; is the set of the fixed effects of the covariates stored in the design matrix **;** is an identity matrix; is the residual variance in the regression; are the random effects for the SNPs stored in the design matrix ***V*** (dimension ), and is the distribution for the weight parameters. That is, the random regression weights, are marginalized over independent Normal distributions with equal variance .

Equivalently, and more typically, the log likelihood is written with random effects marginalized out, where the genetic similarity (called the kernel in some contexts), , is given by **=**, as is the case, for example, when is the realized relationship matrix ([@btt177-B14]; [@btt177-B24]). Given this equivalence, the SNPs used to estimate genetic similarity (those in ) can be interpreted as a set of covariates in the regression.

In our model, we partition the random effects into two sets: one set of random effects, (with design matrix ), is used to correct for confounders (and condition on causal SNPs) using SNPs, whereas the other set, , is used to test the SNPs of interest in the corresponding design matrix, . The log likelihood (in the linear regression view) is then written where each set of random effects has a separate variance ( and ). Again, we can equivalently write this in the marginalized form,

For convenience, we re-parameterize this as where now the covariance matrix, , has been partitioned into two variance components: using ( is of dimension ) to account for confounders and ( is of dimension ) to model signal from a pre-defined set of SNPs of interest, such as those within a gene. The scalar parameter is estimated from the data by, for example, restricted maximum likelihood. The null model for our set test is given by , whereas the alternative model allows 1 ≥ τ ≥ 0.

Until lately, estimating the parameters and computing the likelihood of a LMM was cubic in the number of individuals. However, we have recently shown that when the number of SNPs used to estimate genetic similarity, , is less than the cohort size, , and when genetic similarity matrix, , factors as ( of dimension ), then the computations (and memory requirement) become linear in ([@btt177-B24]). So far this result has been applied in the context of correcting for confounders in a univariate GWAS with just a single variance component. Originally the SNPs for inclusion in were obtained by sampling SNPs genome-wide and relying on linkage disequilibrium ([@btt177-B24]). However, in light of the equivalence with linear regression, it became clear that one should choose the SNPs with feature selection as one would do in any statistical modelling problem ([@btt177-B25]; [@btt177-B28], [@btt177-B27]). For example, one can do an uncorrected univariate scan of the SNPs to select those which should be used to correct for confounders (and causal SNPs to condition on), and this is precisely the approach we take here, just as in ([@btt177-B25]; [@btt177-B28]).

Thus, in our approach, we select SNPs for by first sorting all available SNPs according to their univariate linear-regression *P*-values (in increasing order) and then evaluate the use of more and more SNPs in order until we find an optimal number of SNPs ([@btt177-B28]). This resulted in 650 and 310 SNPs for the Genetic Analysis Workshop 14 (GAW14) and Crohn's analyses, respectively. Additionally, any SNPs that were being tested (i.e. those in ), and those within 2 centimorgans, were removed from so as not to contaminate the null model ([@btt177-B28]). This type of approach for correction of confounders in univariate tests has previously been demonstrated to work well on a broad range of datasets ([@btt177-B28]). The same conclusions apply for a variant of this approach using out-of-sample prediction ([@btt177-B25]).

For estimation of variance parameters and computation of the likelihood ratio test (LRT) statistic, we use restricted maximum likelihood, which is itself a valid likelihood for the LRT and can be computed in the same time and memory complexity as the (unrestricted) likelihood. Details on efficient parameter estimation are provided in ([@btt177-B24]).

When testing sets in an uncorrected manner, that is, without accounting for confounders (which we did for comparison purposes), we omitted the portion of the variance that corrected for confounders, . In particular, we set and tested the significance of with the same LRT described next.

2.1 *P-*value computation {#SEC2.1}
-------------------------

We have now fully specified our model for doing set tests when confounders are present. To obtain a *P-*value on the set of SNPs of interest, such as those belonging to a gene (i.e. those in ), we use an LRT. In particular, to test the significance of the set of SNPs of interest, we compare the maximum restricted likelihood of the data with and without the set of SNPs of interest, that is, the maximum restricted likelihood of the alternative and null models. More formally, our null hypothesis is given by τ = 0, whereas our alternative hypothesis is given by .

To obtain calibrated *P*-values, we require an accurate estimate of the distribution of statistics under the null hypothesis. However, obtaining a sufficiently accurate estimate of this distribution is not straight-forward. Standard software uses a parametric form for this distribution of ---a 50--50 mixture of two distributions, the first with zero degrees of freedom and the other with one degree of freedom. The former accounts for the fact that the tested parameter is on the boundary of the allowed space in the null model ([@btt177-B8]; [@btt177-B37])---that is, to account for the fact that in the null model and 1 in the alternative. The necessary regularity conditions for this null distribution to hold, include that the outcome variable can be partitioned into a large number of identically and independently distributed sub-vectors ([@btt177-B13])---conditions that are not generally met in our setting because individuals may be arbitrarily related to one another. It has been shown that when the regularity conditions are not met, the distribution yields conservative *P*-values ([@btt177-B13]) because the mixing weight on the component is too low at 50%. We have also found this to be the case in our setting ([Table 1](#btt177-T1){ref-type="table"}). Table 1.Type I error estimates for FaST-LMM-Set using one million tests across various levels of significance, αSignificance levelFast-LMM-setNon-truncated ML**\*\*\*\*\***[^2]

Although one might consider use of a parametric bootstrap to estimate the null distribution, (e.g. [@btt177-B13]), such an approach dramatically increases the running time over computation of the test statistics themselves because of the extremely large number of bootstrap test statistics needed. Yet, another alternative is to use an empirical distribution based on permutations, which faces a similar problem. However, one can use many fewer permutations by instead assuming a parametric form of the null distribution and then fitting the few required parameters to the test statistics generated from the permutations ([@btt177-B20]). It is such an approach that we take here. This approach assumes that the null distribution of test statistics is the same across all tests, an assumption that has also been made in the small sample correction in SKAT-O and elsewhere ([@btt177-B12]; [@btt177-B13]; [@btt177-B20]).

The parametric form of the null distribution that we assume, and to which we fit null distribution test statistics to, is inspired by ([@btt177-B12]; [@btt177-B13]), who reported that a mixture of and , where is the scaling parameter for the scaled chi-square distribution, yielded good type I control when testing a variance component in a single-component LMM. We use the same parametric form of the null distribution, except, to gain additional flexibility for the two-component LMM, we allow the degrees of freedom on the second component, , to be different from 1 (finding this to be useful in the sense that we estimate ). That is, we use the null distribution, with free parameters , and . Using this distributional form, we found that a fit of the free parameters to the (full collection of test) statistics yielded *P*-values that were too liberal in the tail ([Table 1](#btt177-T1){ref-type="table"}). Thus, we instead fit our parametric parameters using only the most significant tail of the null distribution of test statistics---in particular, the top 10% of null test statistics (In our experiments with just a single variance component, *P*-values were also liberal in the tail---those for which *P* \< 0.05. This regime was not examined by Greven *et al.*).

We now describe the details of our approach for estimating the free parameters, , and , of this null distribution. To generate a single null test statistic for a set, we permuted the individuals for only the SNPs in that set. Because we do not permute the SNPs (rather, the individuals), the pattern of linkage disequilibrium between the SNPs within a single test remains intact. Although we permute the individuals, who are not (generally) identically and independently distributed, we do so only for the SNPs in the test set, leaving any confounding signal among the covariates, the confounding SNPs and the phenotype intact. We found that null distribution parameter estimates stabilized with the use of 10 permutations per test (for both WTCCC and GAW14). Thus, our procedure has a runtime roughly a factor of 10 larger than if we had not needed permutations. Within a gene, we use the same permutation for all SNPs, and we used the same 10 permutations across all sets.

Given this permutation-generated sample of test statistics from the null distribution, we fit the parameters , *a* and *d* as follows. The distribution is a Dirac delta function at 0---that is, this component of the null distribution yields only test statistics of 0, and correspondingly *P* = 1. Furthermore, the yields a test statistic of 0 with measure zero. Consequently, one can obtain good estimates of the parameters simply by assuming that precisely those tests with variance parameter estimate belong to the component, and then estimating as the proportion of tests belonging to this component. We then estimate and directly from the non-zero test statistics (those likely to belong to the component) using a regression in which these parameters are adjusted such that resulting LRT *P*-values have the least squared error with the theoretical *P*-values (derived conditionally on an estimate of π). Specifically, we use the log *P*-value squared error and only use the smallest 10% of *P*-values in the regression. This truncated regression approach consistently yielded calibrated quantile--quantile plots ([Fig. 1](#btt177-F1){ref-type="fig"}) and also controlled type I error ([Table 1](#btt177-T1){ref-type="table"}). Furthermore, it yielded better power than the score test ([Table 2](#btt177-T2){ref-type="table"}). Fig. 1.Quantile--quantile plot of observed and expected log~10~ *P*-values on the null-only WTCCC datasets (same data as used for [Table 1](#btt177-T1){ref-type="table"}) for FaST-LMM-Set. Dashed red error bars denote the 99% confidence interval around the solid red diagonal. Points shown are for null-only data (generated by permuting individuals in the SNPs to be tested---see Section 2) and only for the non-unity *P*-values (those assumed to belong to the non-zero degree of freedom component of the null distribution). The portion of the expected distribution of *P-*values shown is uniform on the interval \[,1\], where is the estimated mixing weight in the null distribution Table 2.Power experimentsLRTscore*P*-value44260.0360390.031721380.055565090.14241921950.0009[^3]

In summary, our overall approach is as follows: (i) for each set to be tested, permute the individuals of the SNPs belonging to this set, all in the same manner; (ii) compute the restricted LRT statistic for this permuted data to obtain a test statistic from the null distribution; (iii) repeat step 1 ten times; (iv) estimate the proportion of test statistics drawn from the component, , as the proportion of tests in which the parameter τ = 0; (v) use the largest 10% of test statistics to perform a regression to fit the component---that is, find and , which minimize the squared error of the -values with their theoretical values \[uniform distribution on (, 1)\]; and (vi) compute the test statistic for all sets (non-permuted data) and then compute the corresponding *P*-values for these using the null distribution .

In application to real data (described next), our procedure yielded 0.961, on the GAW14 data, and a = 1.41, on the WTCCC data.

2.2 Datasets and other methods {#SEC2.2}
------------------------------

The first dataset was obtained from the GAW14 ([@btt177-B10]). It consisted of autosomal SNP data from an Affymetrix SNP panel and a phenotype indicating whether an individual smoked a pack of cigarettes a day or more for 6 months or more. The cohort included over eight ethnicities and numerous close family members---1034 individuals in the dataset had parents, children or siblings also in the dataset. In addition to the curation provided by GAW, we excluded a SNP when either (i) its minor allele frequency was \<0.05, (ii) its values were missing in \>10% of the population or (iii) its allele frequencies were not in Hardy--Weinberg equilibrium (*P* \< 0.001). In addition, we excluded an individual when \>10% of SNP values were missing. After filtering, there were 7579 SNPs across 1261 individuals.

The second dataset comprised the WTCCC 1 data and consisted of SNP and phenotype data for seven common diseases: bipolar disorder, coronary artery disease, hypertension, Crohn's disease, rheumatoid arthritis, type-I diabetes and type-II diabetes ([@btt177-B38]). Each phenotype set contained ∼1900 individuals. In addition, the data included a set of ∼1500 controls from the UK Blood Service Control Group (NBS). The data did not include a second control group from the 1958 British Birth Cohort (58C), as restrictions on it precluded use by a commercial organization. Our analysis for the Crohn's phenotype used data from the NBS group and the remaining six phenotypes as controls ([@btt177-B23]). We filtered SNPs as described by the WTCCC ([@btt177-B18]) and additionally excluded an SNP if either its minor-allele frequency was \<1%, it was missing in \>1% of individuals or its genetic distance was unknown. After filtering, 356 441 SNPs remained. Unlike the approach used by the WTCCC, we included non-white individuals and close family members to increase the potential for confounding and thereby better exercise the LMM. In total, there were 14 925 individuals across the seven phenotypes and control, as in our previous work ([@btt177-B24]; [@btt177-B23]; [@btt177-B28]). We concentrated our evaluations on Crohn's disease, as inflation for this phenotype was greatest with an uncorrected univariate analysis.

For the WTCCC data, we grouped SNPs into gene sets using gene positions provided on the USCSC Genome Browser (<http://genome.ucsc.edu/>) ([@btt177-B9]; [@btt177-B17]) using build hg19 (we also converted the original WTCCC annotations to this build), which yielded 13 850 gene sets. Because the GAW14 SNPs mapped to only 251 non-singleton gene sets with this strategy, we instead formed sets for this dataset by using overlapping 1 centimorgan windows, yielding 2157 sets. For WTCCC, the set sizes ranged from 1 to 748, with a mean value of 11 and a standard deviation of 24. For the GAW14 data, the set sizes ranged from 2 to 38, with a mean value of 5 and a standard deviation of 4. More generally, this approach of forming sets from windows of nearby SNPs along the genome could be used to map an entire genome into sets, even when the SNPs do not lie in genes. However, it is not our goal here to evaluate different ways in which one might group SNPs, but instead to demonstrate that we can test sets of SNPs in the presence of confounders.

All analyses assumed additive effects of a SNP on phenotype, using a 0/1/2 encoding for each SNP (indicating the number of minor alleles for an individual). Missing SNP data were mean imputed. Multiple testing was accounted for with a Bonferroni correction.

In counting hits for Crohn's disease ([Table 4](#btt177-T4){ref-type="table"}), we omitted any genes found in the major histocompatibility complex (MHC) region because this region is complicated by long-range linkage disequilibrium. We used positions 29--34 Mb on chromosome 6 as the boundaries of the MHC, as suggested by the MHC-sequencing consortium ([@btt177-B30]).

2.3 Experimental setup to assess control of type I error and power {#SEC2.3}
------------------------------------------------------------------

We used synthetic data based on the real WTCCC data to assess the quality of our new method, as well as to compare it against a score test. In particular, to assess type I error, we used all SNPs from the WTCCC dataset, and then permuted the individuals for SNPs in each set tested so as to create null-only test statistics. We permuted the data in this way a total of 72 times, yielding 997 200 null test statistics (because 13 850 sets were tested for each dataset). We additionally permuted another 10 datasets to estimate the parameters of the null distribution () as prescribed by our approach.

For assessment of power, we again used all SNPs from the WTCCC dataset and then generated synthetic phenotypes using an LMM. To do so, we first we fit the null model to the real data to obtain estimates of the parameters and . Then we used the model , with confounding variance equal to estimated environmental noise, , and genetic variance, , equal to the estimated genetic variance . Furthermore, we used the same 310 confounding SNPs for as used on the real data while using all 321 839 SNPs further than 2 centimorgans away from those in as the causal SNPs for (those contained in the true positive sets in our power experiments). We generated five phenotypes in this way. The resulting phenotypes behaved much like the real data in that, on average, we found 10 Bonferroni-corrected sets on each of five datasets, as compared with the 23 found on the real data (note that [Table 4](#btt177-T4){ref-type="table"} does not include SNPs from the MHC region and therefore shows only 16). For both type I error and power experiments, we tested the same gene sets as on the real data, except for power, we did not include any gene sets containing SNPs in the (those SNPs used to correct for confounding) or within 2 centimorgans of these SNPs, to be sure that the sets were unambiguously true positives.

When comparing our LRT approach against a score-based test, we used the same score test as the Sequence Kernel Association Test (SKAT) ([@btt177-B40]), which uses the Davies method to compute *P*-values from the null distribution (but here with our FaST-LMM-Set model). This score test has previously been shown to control type I error ([@btt177-B20]), consistent with our own findings (not shown).

2.4 Linear-time computations {#SEC2.4}
----------------------------

What remains left to explain is how to achieve the linear-time speedup in the present setting---the case of two random effects. The crux of the cubic to linear-time speedup in the single random effect model was to bypass construction of and the required spectral decomposition of by recognizing that one can instead use and the spectral decomposition of ([@btt177-B24]). We can view the two random-effects model as a single random effect with covariance . To use the algebraic speed-up just mentioned, we observed that , where now using to denote the side-by-side concatenation of matrices and . So long as , which was true for all of the datasets examined here (and almost all others we have analyzed), we obtained the linear-time computations and memory footprint just as in [@btt177-B24]. \[One might also consider using low rank update equations of the type used in [@btt177-B28] to perform exclusion, although we have not yet implemented this.\] Finally, to perform parameter estimation in this two random-effects model, we used an approach similar to that reported in [@btt177-B24]. That is, we used a 1D Brent search optimization routine to find the value of , which maximized the restricted likelihood. For each call to the restricted likelihood for a particular value of , efficient computations were performed as in ([@btt177-B24]), except using the two random effects.

3 RESULTS {#SEC3}
=========

3.1 Type I error and power on synthetic data {#SEC3.1}
--------------------------------------------

First, we examined whether our LRT approach controlled type I error. As described in Section 2, we generated null-only test statistics by way of permutations on the WTCCC data, obtaining a total of roughly 1 million test statistics. The type I error was controlled ([Table 1](#btt177-T1){ref-type="table"}). Neither (1) fitting the null distribution parameters (to all test statistics) by way of maximum likelihood nor (2) use of a null distribution, yielded calibrated *P*-values. The first was liberal, whereas the latter was conservative ([Table 1](#btt177-T1){ref-type="table"}). Finally, quantile--quantile plots in [Figure 1](#btt177-F1){ref-type="fig"} additionally demonstrates good calibration over the entire range of *P*-values from our method, for the same points as in [Table 1](#btt177-T1){ref-type="table"}. Because the score test we used has already been shown to control type I error ([@btt177-B20]), we do not report on it here, but we did find the same in our own experiments (not shown).

Next, we compared the power of our LRT approach to a score test approach (both using the same two random effects model) on synthetic data (see Section 2). Over five synthetic datasets and a range of significance levels, LRT found significantly more sets than the score test ([Table 2](#btt177-T2){ref-type="table"}). Furthermore, on the real WTCCC data, LRT again found significantly more sets ([Table 4](#btt177-T4){ref-type="table"}).

3.2 Application to real data {#SEC3.2}
----------------------------

We investigated our new approach on two datasets. The first was the GAW14, which included data from over eight ethnicities and numerous close family members for a total of 1261 individuals. After filtering, there were 7579 SNPs available for analysis. The second dataset was from the WTCCC from which we used 14 925 individuals and 356 441 SNPs in our analysis. We used the Crohn's phenotypes because this was the one showing the most confounding in an uncorrected analysis. Unlike the WTCCC ([@btt177-B38]), we included non-white data for individuals and close family members to increase power and because the LMM can treat them properly ([@btt177-B1]; [@btt177-B16]; [@btt177-B31]).

To judge the degree of confounding due to genetic relatedness, and to ensure that our LMM approach could sufficiently correct for confounding, we ran both an uncorrected and corrected *univariate* analysis on each dataset because this is a well-understood test that has been reported on before. Here, the extent of test statistic inflation owing to unmodelled confounders was assessed using the λ statistic, also known as the inflation factor from genomic control ([@btt177-B43]). The value λ is defined as the ratio of the median observed to median theoretical test statistic. Values of λ substantially greater than (less than) 1.0 are indicative of inflation (deflation). As can be seen in [Table 3](#btt177-T3){ref-type="table"}, without correction, the test statistics appear to be inflated. Although one might consider (seen on the corrected analysis of WTCCC) as still moderately inflated, it has been shown that complex, highly polygenic traits lead to increases in ([@btt177-B41]) in the absence of spurious signal. Moreover, the WTCCC themselves reported in the range of 1.08--1.11 on removal of individuals from different races and related individuals (neither of which we removed), and also on adjustment with two principal components, suggesting that a of 1.08 is the result of polygenic influence ([@btt177-B38]). Table 3.of univariate tests for confounding-corrected and naïve methodsMethodGAW14WTCCCUncorrected3.801.30FaST-LMM1.011.08[^4]

Having established that both of our datasets required correction for confounders and that the LMM with our chosen background genetic similarity matrix, , sufficiently corrected for confounders, we next applied FaST-LMM-Set, using the same LMM-correcting component as in the univariate test. The full set of results is available for all analyses in [Supplementary Table S1](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt177/-/DC1). On GAW14, the uncorrected set analysis yielded 241 significant sets, whereas FaST-LMM-Set, which corrects for confounding, yielded none. It is thought that this dataset contains little, if any signal (e.g. based on the univariate analysis). On WTCCC Crohn's disease, an uncorrected set analysis yielded 26 significant sets, whereas FaST-LMM-Set yielded 16 ([Table 4](#btt177-T4){ref-type="table"}). Next, we investigate these sets in detail. Table 4.Validation of methods on WTCCC Crohn's diseaseMethodIn meta- analysisSupported by literatureNo support foundFaST-LMM-Set1510FaST-LMM-Set-Score700FaST-LMM-Set (uncorrected)1736[^5]

To validate the significant sets recovered on the WTCCC Crohn's phenotype, we used a meta-analysis ([@btt177-B11]; [@btt177-B28]). If a set we found as significant was within 50 kilobases of a validated SNP/region, we counted it as a true positive. Additionally, for the genes not validated by the meta-analysis, we conducted a literature search. Detailed validation results are provided in [Supplementary Table S1](http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btt177/-/DC1). Using our newly developed method, FaST-LMM-Set, we found 16 significant gene sets, of which all but one were validated by the meta-analysis. The remaining gene, SLC24A4, performs a similar function to the validated gene SLC22A4---both are cation transporters \[[www.genecards.org](www.genecards.org) ([@btt177-B34])\]---suggesting a promising candidate for follow-up.

3.3 Advantages of set tests over univariate tests {#SEC3.3}
-------------------------------------------------

In the course of our analyses, we noticed that some sets with small *P*-values had almost no univariate signal in any of the SNPs. In particular, among the 16 sets in the WTCCC data supported by either meta-analysis or literature search, six (C1orf141, SAG, SLC24A4, SLC22A4, TCTA and PTPN2) were missed by the univariate analysis (i.e. an SNP lying within 50 kilobases of any of the regions reported by Frank *et al.* was not found to be significant). One of the motivations for doing set analysis is to uncover signals for such regions. The intuition here is the same as in a univariate conditional GWAS analysis. That is, conditioning on variables can lead to an increase in power, revealing signal that would be hidden without the conditioning ([@btt177-B2]; [@btt177-B36]). Thus, the set test acts not only to aggregate weak signal but also to unmask signal hidden by covariates included by virtue of doing a set test. We investigated one such case in detail. In particular, we computed the univariate *P*-values for each of the 15 SNPs associated with the gene SLC22A4, marginally, as well as conditioned on all the other SNPs in this gene, using an LMM to correct for confounding. This gene was found to be associated with Crohn's disease using FaST-LMM-Set with *P* = 7.6 × 10^−8^. The smallest marginal univariate *P*-value was , but when we conditioned on the other SNPs in the set, the smallest conditional univariate *P*-value obtained was . This result demonstrates the increased power afforded by the set test owing to the interplay of SNPs within the gene that is missed by a univariate approach.

3.4 Significance of sets is independent of set size {#SEC3.4}
---------------------------------------------------

On data with phenotypic association, we expected that there could be correlation between set size and *P*-value because with a larger set, there could be more predictive SNPs and more power. Furthermore, we expected that when confounders were not properly accounted for in the set analysis, that the more SNPs in a set, the more power the set would have to detect these confounders, and therefore the stronger the correlation between set size and *P*-value would appear. The correlations on our real data were consistent with these expectations. In particular, we saw no significant correlation for FaST-LMM-Set (which corrects for confounders) but significant correlation when we did not correct for confounders ([Table 5](#btt177-T5){ref-type="table"}). Table 5.Pearson correlation of log~10~(*P*)-values with set sizeMethodFaST-LMM-Set (uncorrected)FaST-LMM-SetGAW14**0.27 ()**0.001 (0.98)WTCCC**0.051 (**0.025 ([^6]

We also expected that on null-only data, when confounders were properly accounted for, the set *P*-value and set size would be independent. Consistent with this expectation, when we permuted the Crohn's phenotype to remove signal, the FaST-LMM-Set correlation was reduced to (*P* = 0.18).

4 DISCUSSION {#SEC4}
============

We have developed a novel efficient approach for testing sets of genetic markers in the presence of confounding structure such as arises from ethnic diversity and family relatedness within a cohort. Application of this algorithm demonstrated that our method corrects for confounders and uncovers signal not recoverable by univariate analysis.

Although we did not analyse rare variant data, we have shown elsewhere that the underlying LMM methodology works well to correct for confounding due to rare variants in a univariate setting ([@btt177-B27]). Furthermore, others have already shown that LMM-based set tests work well for detection of sets of associated rare variants ([@btt177-B40]). It follows that the hybrid approach that we presented here is likely to prove effective in the setting of testing sets of rare variants in the presence of confounders, although this remains to be investigated fully. For example, we have found the use of a linear model on a case--control phenotype to yield inflated tests statistics when testing rare variants.

We have demonstrated that our LRT outperforms a score test for our model and setting. This is perhaps unsurprising, given that the score test can be viewed as an approximation to the LRT by a second-order Taylor series expansion ([@btt177-B6]) in the neighbourhood of the null model. Furthermore, given its robust properties, the LRT is considered the benchmark for statistical testing ([@btt177-B7]). We note, however, that in some recent work ([@btt177-B22]), when testing for rare variants using a logistic fixed effects model, a score test was found to perform better than LRT, which was found to be liberal. Although the best test may depend on context, we note that Lin *et al.* used a different model than we did and, in particular, did not use a variance component approach. Also, they used closed-form asymptotic-based LRT *P*-values rather than making use of empirically derived null distributions as we have done here.

For many cases of hidden structure in genetic data, the use of principal component-based covariates is sufficient for correction ([@btt177-B32]), and thus these covariates could immediately be added to existing models such as SKAT ([@btt177-B40]) to achieve a set test that corrects for confounding. However, it is now widely accepted that there are various forms of confounders, which cannot be corrected for by principal components, but for which an LMM adequately corrects ([@btt177-B16]; [@btt177-B31]; [@btt177-B42]), and it is for these problems that we have developed our approach.

We here focused on testing SNPs in a manner similar to SKAT ([@btt177-B40]). However, it would be straightforward to also adapt FaST-LMM-Set to the approach of SKAT-O, in which the original SKAT model is in effect combined with a collapsing-type approach ([@btt177-B19], [@btt177-B20]).
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[^1]: Associate Editor: Jeffrey Barrett

[^2]: The first row shows results for our LRT-based method; the second row ('non-truncated ML') shows results when fitting the null distribution parameters using maximum likelihood with all test statistics; the third row shows results using a null distribution. Results significantly different from expected according to the binomial test (*P* \< 0.05) are denoted with an asterisk.

[^3]: Number of tests with *P-*values less than α. The last column shows the results of a binomial test comparing the number of tests found by LRT as compared with the score test. The first row denotes the Bonferroni threshold for the WTCCC dataset.

[^4]: FaST-LMM denotes a one-component (to correct for confounding) LMM, testing one SNP fixed effect ([@btt177-B28]); Uncorrected refers to no correction for confounding (linear regression).

[^5]: FaST-LMM-Set denotes our newly developed method, which corrects for confounding and uses our LRT approach; FaST-LMM-Set (uncorrected) is the same but does not correct for confounding with a second variance component; FaST-LMM-Set-Score is the same as FaST-LMM-Set but uses a score test (as described in Section 2) instead of an LRT. Columns: 'in meta-analysis' shows the number of significant sets validated by a meta-analysis ([@btt177-B11]); 'supported by literature' denotes the number of significant sets found by a literature search; 'no support found' denotes the number of sets supported neither by the meta-analysis nor a literature search.

[^6]: FaST-LMM-Set denotes our newly developed method; FaST-LMM-Set (uncorrected) is the same but does not correct for confounding with a second variance component. The *P*-value is reported in parentheses next to the value for . Significant entries are bolded. We excluded *P*-values from the zero degree-of-freedom component of our one-sided test, as their inclusion would violate the assumptions of the Pearson correlation test.
